Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill

West Indian Medical Journal

Volumn 57, Issue 2, 2008, Pages 106-111

  Hosgor Limoncu, M ^a   Ermertcan, S ^a   Tasli, H ^a   Yurtman, A N ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; TIME; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CIPROFLOXACIN; CROSS INFECTION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN;

EID: 48449091464     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21: 8-12.
2. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonasr aeruginosa. Diagn Microbiol Infect Dis 2003; 46: 13-7.
3. Burgess DS, Nathisuwan S. Cefepime, piperacillin/tazobactain, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002; 44: 35-41.
4. Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo, MR. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with β-lactams and amikacin. J Antimicrob Chemother 2005; 56: 353-9.
5. Drago L, De Vecchi E, Nicola L, Colombo A, Guerra A, Gismondo MR. Activity of levofloxacin and ciprofloxacin in combination with cefepime, ceftazidime, imipenem, piperacillin-tazobactam and amikacin against different Pseudomonas aeruginosa phenotypes and Acinetobacter spp. Chemotherapy 2004; 50: 202-10.
6. Samaha-Kfoury JN, Kanj SS, Araj GF. In vitro activity of antimicrobial agents against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. Am J Infect Control 2005; 33: 134-6.
7. Presterl E, Mueller-Uri P, Grisold A, Georgopoulos A, Graninger W. Ciprofloxacin- and methicillin-resistant Stqphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid. Eur J Clin Microbiol Infect Dis 2001; 20: 486-9.
8. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004; 53 (Suppl 2): ii11-21.
9. Dawis MA, Isenberg HD, France KA, Jenkins SG In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentainicin against mulfidrug-resistant organisms. J Antimicrob Chemother 2003; 51: 1203-11.
10. Fung-Tomc JC, Gradelski E, Valera L, Huczko E, Bonner DP. Synergistic activity of the novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species. Int J Antimicrob, Agents 2002; 20: 57-60.
11. Gradelski E, Valera L, Bonner D, Fung-Tomc JC. Synergistic activity of gatifloxacin in combination with other antimicrobial a4gents against Pseudomonas aeruginosa and related species. Antimicrob Agents Chemother 2001; 45: 3220-2.
12. Sader HS, Huynh M Jones RN. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against gram-negative bacilli. Diagn Microbiol Infect Dis 2003; 47: 547-50.
13. Clinical and Laboratory Standards Institute: Methods for Dilution Susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. Villanova, PA, 1997.
14. Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian V (ed): Antibiotics in Laboratory Medicine. 5th ed. New York: Williams and Wilkins; 2005: 365-440.
15. Burgess DS, Hastings RW. Activity of piperacillin/tazobactam in combination with amikacin, ciproftoxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. Diagn Microbiol Infect Dis 2000; 38: 37-41.
16. Bosso JA, Saxon BA, Matsen JM. In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis. Antimicrob Agents Chemother 1990; 34: 487-8.
17. Aronoff SC, Klinger JD. In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P cepacia isolates from children with cystic fibrosis. Artimicrob Agents Chemother 1984; 25: 279-80.
18. Bajaksouzian S, Visalli MA, Jacobs MR, Appelbaum PC. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time kill studies. Antimicrob Agents Chemother 1997; 41: 1073-6.
19. Diez Enciso M. In vitro activity of aztreonam, cefotaxim, cefiazidime and imipenem combined with ciprofloxacin against Gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1991; 10: 90-2.
20. Mayer I, Nagy E. Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp. J Antimicrob Chemother 1999; 43: 651-7.
21. Isenberg HD, Alperstein P, France K. In vitro activity of ciprofloxacin, levofloxacin, and travofloxacin, alone and in combination with beta-lactams, against clinical isolates of Pseudonionas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diagn Microbiol Infect Dis 1999; 33: 81-6.
22. Cappelletty DM, Rybak MJ. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 677-83.